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The liver is the center for drug and xenobiotic metabolism, which is influenced
most with medication/xenobiotic-mediated toxic activity. Drug-induced hepatotoxicity
is common and its actual frequency is hard to determine due to underreporting,
difficulties in detection or diagnosis, and incomplete observation of exposure. The death
rate is high, up to about 10% for drug-induced liver damage. Endorsed medications
represented >50% of instances of intense liver failure in a study from the Acute Liver
Failure Study Group of the patients admitted in 17 US healing facilities. Albeit different
studies are accessible uncovering the mechanistic aspects of medication prompted
hepatotoxicity, we are in the dilemma about the virtual story. The expanding prevalence
and effectiveness of Ayurveda and natural products in the treatment of various disorders
led the investigators to look into their potential in countering drug-induced liver toxicity.
Several natural products have been reported to date to mitigate the drug-induced toxicity.
The dietary nature and less adverse reactions of the natural products provide them an
extra edge over other candidates of supplementary medication. In this paper, we have
discussed the mechanism involved in drug-induced liver toxicity and the potential of
herbal antioxidants as supplementary medication.
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INTRODUCTION
The leading cause of drug non-approval and drug withdrawal by the Food and Drug
Administration (FDA) in the US is drug-induced hepatotoxicity (Ostapowicz et al., 2002; Pandit
et al., 2012). More than a thousand medicines and chemicals have been reported to cause liver
injury (Larrey, 2000; Biour et al., 2004; Upadhyay et al., 2010b; Porceddu et al., 2012). Drug-
induced liver injury may account for approximately 10% of all cases of acute hepatitis, 5% of all
hospital admissions, and 50% of all acute liver failures (Pandit et al., 2012). It is remarkable that
more than 75% of cases of idiosyncratic drug reactions result in liver transplantation or death
(Ostapowicz et al., 2002; Pandit et al., 2012). Drug-induced liver injury is a relatively common
cause of acute liver disease and carries a mortality of around 10% (Lewis and Zimmerman, 1989;
Shapiro and Lewis, 2007; Chalasani et al., 2008; Bell and Chalasani, 2009; Holt and Ju, 2010;
Upadhyay et al., 2010b; Pandit et al., 2012; Björnsson et al., 2013). Inefficient drug metabolism,
as is observed in the renal transplant (RT) recipients with the chronic liver disease, make
them more prone to drug-induced hepatotoxicity (Contreras et al., 2007). Extensive research on
drug-induced hepatic cell damage worldwide has been done in the past and is also an area of
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major concern at present since hepatotoxicity due to these
drugs, when it becomes terminal, results in malnutrition, organ
dysfunction, and death (Björnsson, 2009; Porceddu et al.,
2012).
The liver plays a major role in the metabolism and removal
of drugs (Pandit et al., 2012). Detoxification of drugs and
xenobiotics in the liver by drug metabolizing enzymes (DMEs)
is an important phenomenon in the acquisition of homeostasis
(Upadhyay et al., 2007, 2008). Alteration in homeostatic status
leads to a shift in the dynamic equilibrium of metabolism
toward the ROS generation thereby oxidative stress leading to
organ malfunction. Liver insufficiency and damage resulted from
exposure to environmental toxicants, particular combinations
or dosages of pharmaceuticals, and microbial metabolites are
major causes of disease and death worldwide (Upadhyay
et al., 2007, 2008). Intake of drugs, their metabolism and
removal make a condition of dynamic equilibrium to maintain
homeostasis. Phase I and phase II enzymes play a crucial
role in the metabolism and detoxification of various drugs
and xenobiotics. For the acquisition of dynamic homeostasis,
highly tuned metabolic control of drugs or xenobiotics by
xenobiotic metabolizing enzymes is needed. Any imbalance
in the activity of these enzymes ultimately leads to the
shifting of equilibrium toward free radical generation that
could finally bind to macromolecules such as DNA to cause
mutation, lipid to cause membrane damage, or proteins to
alter their activities (Upadhyay et al., 2007, 2008, 2010a,b).
The generation of reactive intermediates is a common event
in liver damage resulting from a variety of hepatotoxic drugs
and solvents (Coleman et al., 2007). The hepatotoxic reactions
caused by drugs may be summarized as acute reactions (which
consist of hepatocellular necrosis), cholestasis (with or without
inflammation), and miscellaneous reactions; however, some
drugs can cause chronic damage and may even lead to tumor
growth (Table 1). In this article, we have discussed the drug-
induced hepatotoxicity, factors that may add to its toxicity,
mechanism, and prevention.
FACTORS AFFECTING DRUG-INDUCED
HEPATOTOXICITY
There are various factors that enhance a person’s susceptibility
to a potentially hepatotoxic drug (Figure 1). Advancing age,
gender, lifestyle factors, obesity, nutritional status, genetic
background, dose, and duration of drugs may affect the risk
of drug-mediated hepatotoxic reactions. Persons suffering
from other diseases, such as, human immunodeficiency
virus, hepatitis C, rheumatoid arthritis, and systemic lupus
erythematosus, are more prone to toxic drug reactions. Drug
composition and drug-drug interaction may also be a reason
for increased risk of drug-induced hepatotoxicity. For example,
certain drugs containing a nitro-aromatic moiety or drugs
interacting with nuclear receptors such as phenobarbital
may cause organ-selective toxicity or may potentiate the
toxicity of other drugs (Yamazaki et al., 2005; Boelsterli et al.,
2006).
TABLE 1 | Common hepatotoxic reactions.
Drugs Hepatotoxic reactions
Acetaminophen Acute, direct hepatocellular toxicity,
chronic toxicity
Isoniazid
Methyldopa
Allopurinol Miscellaneous acute reactions
Aspirin
Quinidine
Sulfonamides
Valproate
Amiodarone, Chronic toxicity
Methotrexate
Niacin
Rifampicin
Pyrogallol
Vitamin A
Chlorpropamide
Erythromycin-estolate
Phenylbutazone
Acute cholestasis, phenothiazine type
Diclofenac Acute, idiosyncratic hepatocellular
toxicity
Halothane-related anesthetics
Indomethacin
Phenytoin
Propylthiouracil
Hydrocarbons Acute, direct hepatocellular toxicity
Tratcycline
Methyltestisterone Acute cholestasis, steroid type
Oral contraceptives
DRUG-INDUCED DAMAGE
A rising number of cases of acute liver failures are reported
every year in the United States, and drugs contribute majority
of them, e.g., acetaminophen and idiosyncratic reactions due to
other medications (Pandit et al., 2012). Two to five percent of
jaundice cases and over 10% cases of acute hepatitis are also
contributed by drug-mediated side reactions (Pandit et al., 2012).
Several drugs and chemicals have been withdrawn from the
market worldwide due to their hepatotoxic reactions (Bakke et al.,
1995; Shah, 1999; Lee, 2003; Mohapatra et al., 2005; Upadhyay
et al., 2010a,b; Pandit et al., 2012), yet epidemiological studies
are alarming and suggest that the drug trial process should be
more rigorous. Some drugs have been extensively studied in
humans and animals to elucidate the biochemical and molecular
mechanism of drug-induced hepatotoxicity (Upadhyay et al.,
2007, 2008, 2010a,b). Most of the drugs have a signature effect,
and exhibit a pattern of liver injury. Nevertheless, certain drugs
like rifampicin may produce all kind of symptoms associated
with liver injury, ranging from cholestasis, hepatocellular injury,
to even isolated hyper-bilirubinemia. Therefore, the knowledge
of the most commonly used drugs/agents, such as, anti-
tubercular drugs, acetaminophen, diclophenac, pyrogallol, statins
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FIGURE 1 | Factors affecting drug-induced hepatic toxicity. Various factors, such as, advancing age, gender, lifestyle factors, obesity, nutritional status, genetic
background, dose, and duration of drugs may increase the risk of drug-mediated hepatotoxic reactions.
and so forth, and a high index of suspicion are essential in
diagnosis.
RIFAMPICIN
Hepatitis has been reported to occur 0.46% of individuals
undergoing anti-tubercular therapy and receiving anti-tubercular
drugs. The rate of hepatotoxic reaction was much higher in
Indian patients as compared to that reported from developed
countries (Ramachandran, 1980; Alexander et al., 1982; Mindie
andGabriel, 2002). It is readily absorbed from the gastrointestinal
tract (90%) and most of it is bound to plasma proteins in
circulation. The involvement of oxidative stress in rifampicin-
induced hepatotoxicity has been demonstrated previously
in experimental rats (Sodhi et al., 1998). Rifampicin is a
potent inducer of cytochrome P450 action and enhances the
covalent binding of reactive metabolites of acetyl hydrazine
to the macromolecules of hepatocytes leading to hepatic cell
damage (Powell-Jackson et al., 1982; Sinha, 1987). Additionally,
desacetylrifampicin, another reactive metabolite of rifampicin,
also contributes to some of its adverse effects. It has been
reported to modulate the membrane permeability and cause
membrane damage (Rana et al., 2006). Its prolonged exposure
significantly decreases glucose-6-phosphatase activity, which
could be a reason for the increased level of lipid peroxidation
(Koster and Slee, 1980; Saraswathy and Shyamala Devi,
2001). Anti-tubercular drugs increase intracellular calcium
concentration leading to the induction of phospholipase A2
which degrade membrane phospholipids (Karthikeyan, 2005;
Tasduq et al., 2005). Additionally, CYP2E1 activation and fatty
acid accumulation in the liver either due to excessive supply of
lipids to the liver or interference with lipid deposition, has been
documented in the anti-tubercular drug-induced liver disorders
(Anundi et al., 1993; Farombi et al., 1999; Upadhyay et al.,
2007). Anti-tubercular drugs also induce hypercholesterolemia
that might be due to increased uptake of LDL from the blood,
by the tissues (Kissler et al., 2005; Santhosh et al., 2006).
ISONIAZID
Isoniazid, an anti-tubercular drug, is used alone or in
combination with other drugs to eliminate the active (growing)
bacteria. Usually, the therapy with isoniazid is continued for
a longer time (6–12 months) since the bacteria may exist
in a resting state for a longer period of time. The studies
have indicated severe and fatal hepatitis with isoniazid therapy
(Huang et al., 2003; Saukkonen et al., 2006). The frequency
of hepatotoxic reactions are higher in aged patients over 65
years. Additionally, daily alcohol consumption increases the risk
of hepatitis. In the patients receiving isoniazid, the symptoms
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of hepatic damage appear late, usually after 3 months of
treatment.
In the liver, isoniazid is metabolized primarily by N-acetyl
transferase 2 (NAT-2) to acetyl-isoniazid, which subsequently
is converted to mono-acetyl hydrazine (MAH) and non-toxic
diacetyl hydrazine, as well as other minor metabolites (Huang
et al., 2002; Saukkonen et al., 2006). Studies have revealed
that reactive metabolites of MAH are toxic to tissues due
to ROS generation (Mitchell et al., 1975; Saukkonen et al.,
2006). Isoniazid inhibits glutathione biosynthesis, activities of
antioxidant glutathione peroxidase and catalase activity in
rats (Sodhi et al., 1996; Attri et al., 2001; Saukkonen et al.,
2006). Furthermore, acetyl-hydrazine, a metabolite of isoniazid,
causes damage to hepatic cells by covalently binding to liver
macromolecules (Mitchell et al., 1975; Saukkonen et al., 2006). In
an epidemiological study, it has been reported that homozygous
CYP2E1 c1/c1 host gene polymorphism, which results in
enhanced CYP2E1 activity, causes higher risk of hepatotoxicity
in patients (Huang et al., 2003; Saukkonen et al., 2006).
ACETAMINOPHEN
Acetaminophen (APAP) is a commonly used analgesic
and antipyretic, which is relatively safe at recommended
therapeutic doses (Blazer andWu, 2009). However, its associated
hepatotoxicity is a major concern and the leading cause of
drug-induced liver failure in many countries when used at
high doses (Larson et al., 2005; Mitka, 2014; Wang et al.,
2015). Acetaminophen has been extensively studied in order
to understand the mechanism of drug-induced hepatotoxicity.
Its hepatotoxicity pattern is different in various age groups
for example the hepatotoxic incidences are less in neonates
than in older children and adults. It has been suggested that in
neonates, the oxidative enzyme activity is limited therefore the
incidences are less common (Jacqz-Aigrain and Anderson, 2006).
The acetaminophen-induced liver injury leads to a functional
suppression of the immune system as dictated by the hindrance
of a deferred hypersensitivity reaction to dinitrochlorobenzene
(Masson et al., 2007). Subsequent studies with adrenalectomized
mice, recommended a role of corticosterone in the exhaustion of
lymphocytes taking after APAP-instigated liver damage (Masson
et al., 2007). Acetaminophen is metabolized to N-acetyl-p-
benzoquinone imine by CYP enzymes, which is subsequently
detoxified by reduced glutathione (GSH) to a threshold
concentration, after which GSH depletion occur leading to the
covalent binding of the metabolite to the macromolecules (Reid
et al., 2005;Wolf et al., 2007; Olaleye and Rocha, 2008; Saito et al.,
2010; McGill et al., 2012). APAP overdose has been reported
to induce massive necrosis in the liver in animal models. It is
remarkable that only those hepatocytes undergo necrosis in
which acetaminophen-protein adducts formation occur (Hinson
et al., 2004; Saito et al., 2010). It is also suggested that the APAP
toxicity propagates through nitric oxide (NO), which scavenges
superoxide to produce peroxynitrite, thereby causing protein
nitration (3-ntrotyrosine) and tissue injury (Jaeschke et al., 2002;
Hinson et al., 2004). Three-Nitrotyrosine is usually detoxified by
conjugation with reduced GSH. Thus, acetaminophen toxicity
occurs with increased oxygen/nitrogen stress (Hinson et al.,
2004).
PYROGALLOL
Pyrogallol is an anti-psoriatic drug and has been reported to
cause liver damage in mouse and rat models (Gupta et al.,
2002; Upadhyay et al., 2007, 2008, 2010a,b). In the presence of
metal ions under certain conditions in vitro, pyrogallol causes
oxidative damage to macromolecules (Singh et al., 1994). Pro-
oxidant action of pyrogallol is suggested to be the major cause
of harmful effects such as mutagenesis, carcinogenesis and
hepatotoxicity (Akagawa et al., 2003; Upadhyay et al., 2007).
It is suggested that the auto-oxidation property of pyrogallol
due to the attack by reactive oxygen species such as •OH, O−2 ,
and hydrogen peroxides contribute greatly to its pro-oxidant
actions (Cao et al., 1997; Hayakawa et al., 1997; Mochizuki et al.,
2002; Akagawa et al., 2003). Studies have now established the
involvement of toxicant responsive genes for example CYP1A2,
CYP2E1, glutathione-S-transferase, glutathione reductase, and
glutathione peroxidase in pyrogallol-induced membrane damage
and hepatotoxicity (Upadhyay et al., 2007, 2008, 2010a,b).
DICLOFENAC
Diclofenac-mediated liver toxicity is a prime example of
idiosyncratic liver injury (Mitchell et al., 1973) and the increased
hepatotoxicity markers have been noted in about 15% of
patients receiving diclofenac regularly. Elderly females are
more susceptible to diclofenac-induced liver injury. (Banks
et al., 1995; Kaplowitz, 2001; Mitchell and Hilmer, 2010)
Diclofenac predominantly exhibits hepatocellular pattern of
liver injury; however, cholestatic pattern of liver injury
and cases resembling autoimmune hepatitis have also been
observed (Aithal, 2004). Metabolism of diclofenac by Cyp2C8/9
or by UDP-glucuronosyltransferase-2B7 results in unstable
intermediate compounds that modify proteins covalently and
increase the risk of hepatotoxicity. Additionally, covalent binding
of reactive metabolites to “self ” proteins results in the formation
of neoantigens, which could be recognized by helper T cells
leading to their activation and an effector-cell response. It is
remarkable that hepatocytes express MHC I molecules on their
surfaces andmay present diclofenac adducts, making them prone
for T-cell mediated liver injury. Alternatively, diclofenac adducts
on the plasma membrane of hepatocytes may be recognized
by B cells resulting in their maturation into plasmacytes, the
secretion of antibodies and ultimately immunological destruction
of hepatocytes (Aithal, 2011).
STATINS/HMG-CoA REDUCTASE
INHIBITORS
Statins are the widely used drugs in the Western countries
including United States. Statins inhibit the process of cholesterol
biosynthesis by competitively inhibiting HMG-CoA reductase.
Further, they also decrease the low-density lipoprotein levels
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and increase the atherosclerotic plaques stability (Jacobson,
2006). The use of higher statin doses is shown to exhibit
biochemical abnormalities of liver function as indicated by
moderate elevations of hepatotoxicity markers in animal models
(Horsmans et al., 1990). High doses of derivatives of statins,
lovastatin and simvastatin, have been shown to cause significant
hepatocellular necrosis in rabbits and guinea pigs respectively
(Horsmans et al., 1990). Nevetheless, hepatocellular necrosis
by statins is rarely observed in humans (Alonso et al.,
1999).
OTHER DRUGS
There are some other commonly used drugs that cause liver
damage, for example, valproic acid, an antiepileptic drug, may
cause liver damage in approximately 20% patients; antibiotics
namely ciprofloxacin, erythromycin, amoxicillin may produce
symptoms ranging from jaundice, acute hepatotoxicity to liver
malfunction; chlorpromazine is found to produce symptoms of
jaundice; amiodarone causes acute hepatotoxicity in both animal
and human studies; oral contraceptives may cause jaundice and
cholestatic liver injury and so forth.
UNDERSTANDING THE MECHANISM OF
HEPATOTOXICITY
Mechanism of drug-induced hepatotoxicity is variable and
complex (Figure 2). Some drugs are directly toxic and begin
to exhibit hepatotoxic reactions, which are dose related, within
hours of exposure, whereas others may produce liver injury
only in susceptible people and symptoms appear after few
days or weeks. These reactions are rarely allergic or more
accurately described as idiosyncratic. Drug-drug interaction,
though the drugs are not hepatotoxic themselves, may also
play a critical role in the propagation of toxicity (Yamazaki
et al., 2005). The pathogenesis of drug-induced toxicity
mediated by reactive metabolites has been a center of research
enthusiasm since spearheading examinations in the 1950s
uncovered the connection between these metabolites and
chemical carcinogenesis (Park et al., 2005). A major cause
of hepatotoxic reactions may be drug-induced intrahepatic
cholestasis, which often occurs during the drug discovery and
development process. The vital roles of ROS in the cellular
damage are widely investigated and it has been suggested that
the covalent binding of ROS as well as reactive intermediates
to macromolecules could likely contribute to the severe harmful
drug reactions (Racknagel et al., 1989; Masubuchi et al., 2007).
There are several studies that suggest the generation of reactive
metabolites and free radicals from hepatotoxic drugs (Racknagel
et al., 1989; Park et al., 2005). Membrane lipid peroxidation is
directly related to the depletion of tissue GSH (an intracellular
antioxidant) leading to the altered functional integrity of these
structures and if the damage is sever, it could be fatal (Ross,
1988; Guven and Gulmez, 2003). Membrane lipid peroxidation
may lead to alteration in membrane fluidity and permeability,
enhanced rates of protein degradation, and ultimately cell death
(García et al., 1997). The assumption is upheld by the way
that oxidative damage to erythrocytes causes loss of membrane
capacity by enhancing lipid peroxidation (LPO) and modifying
the erythrocyte antioxidant framework (Vajdovich et al., 1995).
The concentration of intracellular GSH, therefore, is the key
determinant of membrane integrity and the extent of toxicant-
induced hepatic cell injury (Ross, 1988; Guven and Gulmez,
2003).
DRUG-METABOLIZING ENZYMES (DMEs)
DMEs and transporters are key factors that affect the disposition
of xenobiotics (Cheng et al., 2005). These DMEs include mix
function oxidases and phase II backupmachinery that are actively
involved in the detoxification process. Recently, the roles of
transporters (Phase III enzymes) also have been implicated in the
detoxification procedure.
PHASE I ENZYMES (MIXED FUNCTION
OXIDASES)
Cytochrome P450 (CYP), a super gene family of heme-
containing, mixed function oxidase enzymes, are involved in
the metabolism of endogenous steroid hormones, vitamins,
endobiotics (fatty acid derivatives), various drugs/xenobiotics,
and are readily inducible by many exogenous and endogenous
substances (Nelson et al., 1996; Ahmed and Pawar, 1997).
The CYP-catalyzed oxidation of xenobiotics generate a highly
electrophilic intermediates capable of forming covalent adducts
with critical cell macromolecules, such as thiol-containing
membrane proteins that direct Ca++ homeostasis (Bellomo
and Orrenius, 1985; Dahm and Jones, 1996; Vessey, 1996).
The activation of increased intracellular calcium may be the
regular pathway promoting cell death. CYP-mediated reduction
of halogenated hydrocarbons, for example, carbon tetrachloride
or halothane, can likewise create free radical intermediates,
which can straightforwardly harm cell layers through lipid
peroxidation, or can target nucleophilic DNA deposits (Thor and
Orrenius, 1980; De Groot and Noll, 1983; Racknagel et al., 1989;
Dahm and Jones, 1996).
Phase I reactions, catalyzed by various drugs and xenobiotics,
are mediated by various isoforms of CYPs and are regulated
through various nuclear receptors. Phase I enzyme impelling by
classes of microsomal inducers happens by means of enactment
of transcription factors, for example, aryl hydrocarbon receptor
(AhR), constitutive androstane receptor (CAR), pregnane X
receptor (PXR) and peroxisome proliferator-actuated receptor
α (PPARα) (Cheng et al., 2005). Various isoforms of CYP
are reported to be involved in the metabolism and therefore
bioactivation of drugs. CYP3A, CYP2D, and CYP2C sub-families
are involved in the metabolic activation of 50%, 25%, and
20%, respectively, of the currently used clinical drugs (Rendic,
2002; Deng et al., 2008). CYP1A2, 2C7, 2C11, 2D2, 2E1,
2B1/2, and 3A1/2 are the major CYP isoforms involved in the
drug metabolism in rats (Kobayashi et al., 2002; Deng et al.,
2008). Involvement of CYP2E1 and 1A2 in the acetaminophen
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FIGURE 2 | Overview of mechanism of drug and xenobiotic metabolism and effects of herbal antioxidants. Induction of nuclear receptors by drugs and
xenobiotics lead to translocation in the nucleus where they increase the expression of cytochrome P450 enzymes. The activity of these enzymes generates reactive
metabolites and free radicals which in turn bind to macromolecules, cause membrane lipid peroxidation, and increase cellular toxicity. Natural products increase the
expression of phase II enzymes, the level of intracellular antioxidant (GSH), and antioxidant enzymes. The natural products may also inhibit the activities of cytochrome
P450 enzymes in order to attain dynamic homeostasis and reduce cellular toxicity.
and pyrogallol activation has been well established in animal
models (Raucy et al., 1989; Snawder et al., 1994; Upadhyay
et al., 2007). The activation of paracetamol to N-acetyl-para-
benzoquinoneimine (NAPQI) is catalyzed by CYP2E1, 3A4, and
1A2 in humans (Raucy et al., 1989; Snawder et al., 1994). The
involvement of CYP2E1 in rifampicin and ethanol-induced liver
toxicity has also been reported (Jaeschke et al., 2002; Upadhyay
et al., 2007).
REGULATION OF PHASE I ENZYMES:
NUCLEAR RECEPTORS
Regulation of phase I enzymes, particularly CYPs is coupled
with various transcription factors also called nuclear receptors
(NR). These are the largest known family of transcription
factors that modulates the tissue gene expression and are
associated largely with metabolism, developmental function, and
cell differentiation. There are 49 known members of the nuclear
receptor superfamily and each share key structural features
(Urquhart et al., 2007; Woods et al., 2007). These are the
targets of approximately 10–15% pharmaceuticals and explore
about $400 billion global pharmaceutical markets (Woods
et al., 2007). The majority of the nuclear receptors target on
various proteins included in xenobiotic metabolism, in particular,
CYP enzymes (Waxman, 1999; Honkakoski and Negishi,
2000; Johnson and Klaassen, 2002). Several receptors require
heterodimerization with retinoid X receptor (RXR) (Mangelsdorf
and Evans, 1995). Activation of nuclear receptors, for example,
aryl hydrocarbon receptors (AhR), RXR, pregane X receptors
(PXR), and peroxisome proliferator-initiated receptors (PPAR)
are crucial for some clinically imperative drug-drug interactions.
Activation of phase I enzymes by agonists can be ascribed for
activation of signal transduction pathways. Various microsomal
protein inducers display their effects through prompting of
diverse orphan nuclear receptors, therefore enhancing target
gene expression (Denison and Nagy, 2003; Sonoda et al., 2003).
For example, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) binds
to the AhR, which releases the AhR from the cytosolic
tethering protein HSP90, permitting AhR translocation to the
nucleus, heterodimerization with aryl hydrocarbon receptor
nuclear translocator (ARNT), and the binding to xenobiotic
response elements on the CYP1A1 promoter. Also, CAR
ligands affect CYP2B10, PXR ligands incite CYP3A11, and
peroxisome proliferator-initiated receptor α (PPAR α) ligands
activate CYP4A14 (Cheng et al., 2005). The pregnane X receptor
(PXR, NR1I2), a member of the nuclear receptor superfamily,
is activated by a lot of compounds and natural products. It
is involved in the regulation of various CYP isoforms such as
CYP 3A4, which is involved in the metabolism of about 60% of
all prescription drugs (Lehmann et al., 1998; Guengerich, 1999;
Kliewer, 2003). PXR sometimes mediates the protective effects
also in case of some herbal remedies besides its undesirable effects
in patients on combination therapy (Staudinger et al., 2006).
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PHASE II ENZYMES
Detoxification by phase II enzymes eliminates the reactive
intermediates from cellular environments and therefore
decreases the burden of bio-molecular adducts on cellular
homeostasis (Habig et al., 1974; Moon et al., 2006). Phase II
enzymes are mainly involved in the conjugation of activated pro-
toxicants with endogenous bio-molecules like GSH or glucuronic
acid which reduces toxicity and increases water solubility (Habig
et al., 1974; Moon et al., 2006). Glutathione-S-transferases (GST),
a crucial Phase II enzyme, initiates the detoxification process
by catalyzing the conjugation of –SH moiety of glutathione
to xenobiotics, thereby neutralizing the electrophilic sites
and rendering the products more water-soluble. Glutathione
conjugates are thought to be metabolized further by cleavage of
the glutamate and glycine residues, followed by acetylation of
resultant free amino groups of the cysteinyl residue, to produce
the final product, a mercapturic acid (Boyland and Nery, 1969;
Wood and Woodcock, 1970).
REGULATION OF PHASE II ENZYMES
Phase II enzymes are regulated by regulatory elements called ARE
(anti-oxidant response elements), which are situated upstream
to promoter regions (Hayes and McMahon, 2001). Regulation
is coupled with the activation of ARE through activation of a
transcription factor, nuclear erythroid factor 2—related factor
2 (Nrf2; Lee and Surh, 2005). Nrf2 either upregulates or
inhibits transcription of phase II enzymes through ARE by
the heterodimerization with an array of leucine b-zip family
members such as small maf proteins, fos, jun, and so forth
(Jaiswal, 2000; Cheng et al., 2005). Nrf2 is tightly coupled with
Keap1, which acts as a negative regulator of Nrf2 and as a sensor
of xenobiotic and oxidative stresses (Motohashi and Yamamoto,
2004). Nrf2 activation leads to its release from Keap1 followed by
translocation to the nucleus, heterodimerization to other leucine
zipper proteins, and binding to ARE in order to transcriptionally
activate the downstream targets (Motohashi and Yamamoto,
2004). Nrf2 activation is triggered by the ROS modulation in
cells via the interaction of a various signaling molecules specified
by cell types (Hayes and McMahon, 2001). Therefore, most
chemopreventive operators are the modulators of cell ROS and
subsequently activate Nrf2 pathway, which thusly incite phase II
detoxifying response (Hayes and McMahon, 2001). In addition
to the dynamic equilibrium of Phase I and Phase II enzymes,
reduced GSH, glutathione peroxidase (GPx) and catalase (CAT)
are also critical in acquisition of normal cellular physiology as
these are involved in the elimination of lipid peroxides and
toxic oxygen radicals formed during the cellular metabolism
(Trackshel and Maines, 1988; Tanaka et al., 2004; Pal et al., 2006).
Another adoptive cellular response against drugs/toxicants is
the induction of heme oxygenase-1 (HO-1), the rate-limiting
enzyme in the breakdown of heme into carbon monoxide (CO),
iron and bilirubin (Farombi and Surh, 2006). HO-1 is instigated
by oxidative stress stimuli and its enactment is considered an
adoptive survival response (Immenschuh and Ramadori, 2000).
HO-1 impelling possibly provides security against oxidative
damage, for example, in liver ischemia/reperfusion secondary to
transplantation or hemorrhage/resuscitation. Induction of HO-
1 controls the intracellular levels of “free” heme (a prooxidant),
increases the delivery of biliverdin (an antioxidant), enhances
nutritive perfusion, and cultivates the amalgamation of the
Fe-binding protein ferritin to ensure the protection of cells
against oxidative stress (Bauer and Bauer, 2002). CO and
biliverdin/bilirubin, which are generated as a product of HO-
1 activity, have been accounted for the protective effects in
a few organs, including the liver (Farombi and Surh, 2006).
Additionally, HO-1 is an intense defensive component for
cytokine-and CD95-intervened apoptotic liver damages (Sass
et al., 2003). Nevertheless, the heme oxygenase gives a defensive
shield against oxidative stress to a certain level of expression and
a large amounts of HO-1 may even sensitize the cells to oxidative
damage by increasing the level of "free" reactive iron (Bauer and
Bauer, 2002).
ROLE OF TRANSPORTERS
The reduction in expression of uptake transporters, and
augmentation in expression of export transporters, as well
as detoxification enzymes, may prevent the hepatocytes from
accumulating potentially toxic products (Aleksunes et al.,
2005). Therefore, the instances and propagation of liver injury
appears to be a coordinated phenomenon involving both
transport and detoxification genes (Aleksunes et al., 2005). The
phenomenon of extraction and subsequent excretion of drugs
and their toxic metabolites from portal blood is performed by
basolateral and canalicular transporters in hepatocyte plasma
membranes (Arrese and Accatino, 2002). Uptake carriers, such
as organic anion-transporting polypeptides (Oatps) and the
sodium/taurocholate-cotransporting polypeptide (Ntcp), and
export transporters such as multidrug resistance proteins
(Mdrs), multidrug resistance-associated proteins (Mrps), bile
salt export pump (Bsep), and breast cancer resistance protein
(Bcrp) are actively involved in the process of transportation
of drugs/xenobiotics from absorption till excretion (Arrese
and Accatino, 2002; Geier et al., 2002; Song et al., 2003).
The transporters perform specialized functions, for example,
canalicular transporters (Mrp2, Mdrs, Bcrp, and Bsep), are
involved in the excretion of xenobiotics and their metabolites
from hepatocytes into bile, and basolateral transporters (Mrp 1,
3–6) mediate the eﬄux of drugs and chemicals from hepatocytes
into blood (Arrese and Accatino, 2002; Geier et al., 2002; Song
et al., 2003). Various reports are available online implicating the
involvement of these transporters in the xenobiotics metabolism
and propagation of cell injury (Arrese and Accatino, 2002; Geier
et al., 2002; Song et al., 2003; Ghanem et al., 2004; Heijne et al.,
2004).
HERBAL MEDICATION
Herbal antioxidants have attracted the researchers due to its
potential and efficacy against drug-induced liver toxicity. Natural
products used in China and India as traditional medicine for
the treatment of liver disorders are of great interest in these
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days. These are the potential sources for new therapeutic agents
that could be used in the prevention of hepatic injuries. Natural
products rich in triterpenes, flavonoids or polyphenols, have
been now established as powerful hepatoprotective agents in
experimental liver-injury cell and animal models (Table 2; Gupta
et al., 2002, 2004; King and Cousins, 2006; Upadhyay et al.,
2007, 2008, 2010a,b). The basis behind the protection provided
by the natural products is hypothesized to be their antioxidant
property through which they remove the free radicals from the
cellular environment and therefore provide protection against
ROS mediated damage to membrane lipids and macromolecules
(Figure 2; Gupta et al., 2002, 2004; Upadhyay et al., 2007,
2008, 2010a,b). Additionally, the protective potential of natural
products is also contributed by its interaction with various CYP
isoforms, its capability to increase GSH biosynthesis, level of
Phase II/antioxidant enzymes and to inhibit the entry of toxins
to the cells (Figure 2; Gupta et al., 2002, 2004; King and Cousins,
2006; Upadhyay et al., 2007, 2008, 2010a,b; Yarnell and Abascal,
2007). Some of the natural products containing polyphenols are
considered as potential chemopreventive and hepatoprotective
agents. In the last decade, several studies have been conducted
to investigate the mechanism of action of natural products at
biochemical, genomic and proteomic levels. Themost extensively
investigated natural products for hepatoprotection are silymarin,
resveratrol, curcumin and gingko due to their high efficacies, low
or no toxicity and easy availabilities.
SILYMARIN
Silymarin, isolated from the seeds of milk thistle (Silybum
marianum), is an unique flavonoid-complex containing silybinin,
silydianin, and silychristin and have been extensively studied
(Flora et al., 1996; Madrigal-Santillán et al., 2013, 2014). Silibinin
is major constituent of silymarin. Two main mechanisms of
action of silymarin have been proposed based on its cell-
regenerating function and cytoprotective effect. Cytoprotection
is mediated by its antioxidant properties and direct interaction
with cell membrane components (Muriel and Mourelle, 1990;
Mira et al., 1994). Inhibition of lipid peroxidation, as reported
in various in vitro studies using erythrocytes (Valenzuela et al.,
1987), isolated and cultured hepatocytes (Joyeux et al., 1990;
Miguez et al., 1994), and human mesangial cells, is accepted as
one of silymarins major protective mechanisms. Silymarin has
been also reported to have anti-inflammatory (De la Puerta et al.,
1996), anti-fibrotic (Fuchs et al., 1997), and anti-proliferative
effects (Scambia et al., 1996). Diverse biochemical reactions,
such as, the incitement of the synthetic rate of ribosomal RNA
(rRNA) species through the induction of polymerase I and
rRNA transcription, shielding the cell from free radical-mediated
injury and blockage of the uptake of toxins, also contribute to
the protective potential of silymarin (Sonnenbichler and Zetl,
1986; Sonnenbichler et al., 1999; Wellington and Jarvis, 2001).
Silymarin offers protection against enlarged liver by inhibiting 5-
lipoxygenase, production of leukotrienes and generation of free
radicals in Kupffer cells. Moreover, silybin, a major component
of silymarin, protects against the membrane lipid peroxidation
and cellular damage in the mouse hepatocytes (Yin et al., 2011;
Bahmani et al., 2015).
Silymarin has been shown to be effective in combating against
drug-induced hepatotoxicity in various animal models (Gupta
et al., 2002, 2004; Upadhyay et al., 2007). Hepatoprotective
potential of silymarin is suggested to be due to its antioxidant, cell
regeneration and cytoprotection activity (Sonnenbichler et al.,
1999; Gupta et al., 2002, 2004; Upadhyay et al., 2007; Ahmad
et al., 2013; Yang et al., 2014b). It is equally efficient in animals
as well as in humans. It increases the level of glutathione and
glutathione peroxidase in the serum of patients and animals.
Although silymarin has low oral absorption, oral dosages of
420 mg/day have shown some therapeutic potential, with good
tolerability in alcoholic cirrhosis patients. Moreover, daily dose
of silybin (20–48mg/kg) is supposed to be an antidote for acute
mushroom poisoning by Amanita phalloides. Some isoforms of
Silybin have been shown to possess the strongest anti-NF-κB and
anti-HCV activity (Polyak et al., 2007). It has been shown to offer
protection against prostate cancer by the inactivation of erbB1-
SHC (Src homology 2 domain containing) signaling pathway
and induction of CDKIs, and a resultant G1 arrest (Zi et al.,
1998; Zi and Agarwal, 1999). Additionally, it inhibits xanthine
oxidase andmRNA expression of TNF-α, which plays critical role
in mouse skin tumorigenesis (Zi et al., 1997; Sheu et al., 1998).
At lower non-toxic concentrations, it inhibits transformation in
cultured rat tracheal epithelial cells treated with benzo[a]pyrene,
by which chemopreventive compounds that act at early stages
of the carcinogenic process, could be identified (Steele et al.,
1990; Kohno et al., 2002). Protective potential of silymarin against
rifampicin and pyrogallol-induced hepatotoxicity has been found
to be due to its modulatory effect on the augmented level of
CYPs and attenuated level of phase II and antioxidant enzymes
(Upadhyay et al., 2007). In a clinical trial with over 2000 patients
with chronic liver diseases, administration of silymarin extract
for 8 weeks resulted in a significant decrease in liver damage
index in approximately 88% of the patients (Nasri et al., 2013). It
was remarkable that some minor side effects were observed only
in less than 1% of patients (Nasri et al., 2013).
RESVERATROL
Resveratrol (trans-3,4′,5-trihydroxy-trans-stilbene) is a natural
polyphenol present in significant amounts in peanuts, the
skin of grapes and red wine. Potential health benefits of
resveratrol have been widely investigated in past few years.
Its activity in chemoprevention, cardiovascular diseases and
neurodegenerative disorders has been reported in preclinical
studies (Surh, 1999; Frémont, 2000; Ignatowicz and Baer-
Dubowska, 2001; Latruffe et al., 2002; Gescher and Steward, 2003;
Srivastava et al., 2013). Mechanism based inactivation of CYP2E1
and CYP1A2 by resveratrol has been reported previously (Chang
et al., 2001;Mikstacka et al., 2002; Upadhyay et al., 2008). Further,
it has been demonstrated that the metabolic hydroxylation of
resveratrol by CYP1B1, results in its conversion to piceatannol,
a tyrosine kinase inhibitor and a compound of known anticancer
activity (Geahlen and McLaughlin, 1989; Mikstacka et al., 2002;
Potter et al., 2002). The substitution of the hydroxy with methoxy
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TABLE 2 | Natural products, their active ingredients and effects.
Natural products Major constituents Effect References
Barley grass 2-0-glycosylisovitexin (2-0-GIV),
flavone-C-glycosides, saponarin and lutonarin
contain natural SOD
Protect damage by inhibition of fat oxidation
(lipid peroxidation) and by increasing
antioxidant capacity
Duarte, 1995; Markham and
Mitchell, 2003
Carrot Xanthophyll, betacarotene, and other
antioxidant carotenoids
Protects against damage due to powerful
antioxidant capacity of xanthophyll,
betacarotene
Duarte, 1995
Citrus fruit Flavonoids and vitamin C Provides protection against damage by its
antioxidant capacity
King and Cousins, 2006
Eleuthero root (also known
as Siberian ginseng)
Four shogaols contain antioxidants Protects against damage due to its antioxidant
and anti-lipid peroxidative activities
Bol’Shakova et al., 1997;
DerMarderosian, 2001; Yu
et al., 2003
Ginger root About 40 different bioflavonoids, including
proanthocyanidins and quercetin
Protects against damage due to its antioxidant
and anti-lipid peroxidative activities
DerMarderosian, 2001;
Halvorsen et al., 2002; Kim
et al., 2002
Ginkgo leaf About 40 different bioflavonoids, including
proanthocyanidins and quercetin
Protects against damage due to its antioxidant
and anti-lipid peroxidative activities; also
inhibits nuclear factor-kappa B and activator
protein 1 activation, and adhesion molecule
expression in HAECs therefore effective against
atherosclerosis disease
DerMarderosian, 2001;
Chen et al., 2003; DeFeudis
et al., 2003; King and
Cousins, 2006
Grape seed/skin A variety of antioxidant substances and is over
90% proanthocyanidins
Protects against damage by blocking free
radical generation and lipid peroxidatin as well
as by regulating bcl-X(L) gene, DNA damage
and presumably by reducing oxidative stress
Bagchi et al., 2000; Young
et al., 2000;
DerMarderosian, 2001
Kudzu root Isoflavone known as puerarin (its crude form is
more efficient than puerarin)
Protects against damage due to its antioxidant
capacity
Guerra et al., 2000; Allen
et al., 2003; Rezvani et al.,
2003
Milk thistle seed Silymarin (major constituents silybinin) Protects against damage due to its antilipid
peroxidative capacity and antioxidant nature. It
also inhibits CYP isoforms and increases
antioxidant enzymes
Ben-Amotz et al., 1998;
Shimizu, 2001; Kvasnicka
et al., 2003; Upadhyay
et al., 2007
Rosemary leaf Flavonoids such as cirismarin, diosmin,
hesperidin, homoplantiginin, and phegopolin
Protects against damage due to its antioxidant
capacity and have analgesic property for
myalgias and neuralgias
Duarte, 1995; Gruenwald
et al., 2000
Schisandra fruit At least 9 dibenzocyclooctene lignans Protects against damage due to its antioxidant
and anti-lipid peroxidative activities and
decrease the extent of membrane fluidity of
liver microsomes
Lu and Liu, 1992
Tomato Lycopene and vitamin C Protects against damage due to its antioxidant
capacity
King and Cousins, 2006
Turmeric root Curcuminoids Protects against damage due to its antioxidant
capacity and also inhibits different molecules
involved in inflammation such as
phospholipase, lipooxygenase,
cyclooxygenase 2, leukotrienes, thromboxane,
prostaglandins, nitric oxide, collagenase,
elastase, hyaluronidase, monocyte
chemoattractant protein-1, interferon-inducible
protein, tumor necrosis factor, and
interleukin-12
DerMarderosian, 2001
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groups in resveratrol molecules may increase its lipophilicity
and binding to the active sites of CYPs (Chun et al., 2001;
Regev-Shoshani et al., 2004).
Recently it has been shown by Wang et al., that resveratrol
prevents acetaminophen-mediated liver damage by inhibiting
CYP-mediated bioactivation of acetaminophen and regulating
SIRT1, p53, cyclin D1, and PCNA to facilitate liver regeneration
(Wang et al., 2015). Zhang et al., found that pretreatment
of resveratrol effectively reversed As2O3-induced liver toxicity
indices and resulted in a significant improvement in hepatic
function in cat models. Moreover, resveratrol also improved
the glutathione levels, activities of antioxidant enzymes and
attenuated As2O3-induced increases in reactive oxygen species
and malondialdehyde production in liver tissues (Zhang et al.,
2014). Resveratrol has also been shown to offer protection against
methotrexate, sodium fluoride and azozymethane- induced
hepatotoxicity in animal models (Dalaklioglu et al., 2013;
Gurocak et al., 2013; Atmaca et al., 2014).
CURCUMIN
Curcumin is one of the most widely used herbal formulations
to protect drug-induced toxicity. It is the major constituent of
the spice turmeric extracted from the root of Curcumalonga
Linn. It is metabolized to curcumin glucuronides, sulfates,
tetrahydrocurcumin and hexacurcumin in the intestine and
liver of human and rats and is reported to exhibit antioxidant,
anti-inflammatory, choleretic, anti-carcinogenic, antiviral, and
anti-infectious activities (Pan et al., 1999; Joe et al., 2004;
Maheshwari et al., 2006). It inhibits the expression of the
enzyme cyclooxygenase 2 via interference with activation of the
transcription factor NF-κB and is a potential hepatoprotectant
(Plummer et al., 1999; Duvoix et al., 2005; Aggarwal and
Shishioda, 2006). Curcumin may be used in combination
with conventional chemotherapeutic drugs to reverse multi
drug resistance (MDR) in cancer cells and is the most
effective MDR modulator among curcuminoids (Chearwae
et al., 2004). Curcumin attenuates the proliferation of human
lymphocytes and the production of several inflammatory
mediators such as lipid mediators and cytokines and possess
immunosuppressive and anti-rheumatic activity (Fahey et al.,
2007; Gautam et al., 2007; Sandur et al., 2007). Curcuminoids
have also been reported to inhibit pro-inflammatory induction
by enhancing peroxisome proliferator-activated receptor-gamma
(PPAR-gamma) activation (Jacob et al., 2007). Soliman et al.,
showed the curcumin-mediated protection against paracetamol-
induced liver damage by restoring antioxidant activity of liver.
They further showed that curcumin effectively restored the
paracetamol-mediated increase in matrix metalloproteinase-8
(MMP-8), interleukin-1β (IL-1β), IL-8, tumor necrosis factor-α
(TNF-α), and acute phase proteins and decrease in the expression
of antioxidant genes (Soliman et al., 2014). Curcumin offers
hepatoprotection against cisplatin, alcohol and heavy metals-
induced liver damage in animals (Lee et al., 2013; García-Niño
and Pedraza-Chaverrí, 2014; Waseem et al., 2014; Sankar et al.,
2015; Soliman et al., 2015).
GINGKO
The Ginkgo biloba extract possess memory-enhancing,
cognition-improving, immuno-modulating, apoptosis-inducing,
and antiplatelet effects (Oken et al., 1998; Diamond et al.,
2000; Wesnes et al., 2000; McKenna et al., 2001; Mahady, 2002;
Andrieu et al., 2003; Ponto and Schultz, 2003; Yang et al., 2014a).
The therapeutic benefits of this herbal medicine in neurological
disorders, chronic refractory schizophrenia, hepatotoxicity, and
in sleep disturbance of depressed patients have been reported
(Hemmeter et al., 2001; Watanabe et al., 2001; De Smet, 2002;
Yang et al., 2011). The major constituents of ginkgo include
flavonoids (e.g., kaempferol), terpenoids (e.g., ginkgolides
and bilobalaides), and organic acids (e.g., ginkgolic acids and
alkylphenols) (Krieglstein et al., 1995; Jaggy and Koch, 1997;
Tang et al., 2001; Lichtblau et al., 2002; Van Beek, 2002). As an
adjuvant therapeutic drug, ginkgo appears to be promising in
diabetics with respect to ischemic myocardium injury (Schneider
et al., 2008). Intake of Ginkgo biloba extract may alter the hepatic
metabolism by modulating hepatic drug metabolizing enzymes,
altering the level of antioxidant enzymes and endogenous
antioxidants such as GSH. The altered hepatic metabolism may
result in the clearance of co-administered drugs, in particular,
that have reduced renal and liver function (Deng et al., 2008).
OTHER HERBAL MEDICINES
Use of herbs in treatment of various liver disorders is common
in China. The potential of these herbs against diseases with few
and even no side effects continuously increases its popularity
(Table 3). Now these medicines are being gradually accepted
worldwide, particularly in Asia, Europe and North America.
Nevertheless, the application strategy may differ in East and
West due to variety of reasons, such as, philosophical viewpoint,
concept of diseases, and treatment approaches.
In a review published in 2007 on Chinese medicine, the
authors have summarized 274 species (in 216 genera among 92
families) of herbs possessing protective effect against liver toxicity
(Wang et al., 2007). They further suggested a crude classification
of these drugs in two groups; firstly, the main ingredients, for
example silybin, osthole, cumarin, glycorrhizin, flavonoids and
so on; and secondly, the supporting substances like sugars, amino
acids, resins, tannins, and volatile oil.
LIVER INJURY ASSOCIATED WITH
HERBAL PRODUCTS
The drug-induced liver injuries are debated since decades;
the liver toxicity of certain herbal products has only recently
been recognized. There are not many studies available on
this alarming aspect of herbal products till date; however, the
threat cannot be ignored as they may present with the same
spectrum of liver pathologies as synthetic products (Stickel and
Shouval, 2015). A large number of herbal and dietary products
including Shou-Wu Pian (Polygonum multiflorum), Breynia
officinalis, Germander (Teucrium chamaedrys), Chaparral
(Larrea tridentata), Actractylis gummifera, Impila (Callilepsis
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TABLE 3 | A list of herbal medicines and their effects.
Herbal medicines Effects References
Chai Hu Qing Gan Decoction Ameliorates the central necrosis and fatty changes of the liver Lin et al., 2007
Da Cheng Qi Decoction Protects against gastrointestinal disorders, and liver diseases Tseng et al., 2007
Xiao Cheng Qi Decoction Protects against gastrointestinal disorders, and liver diseases Tseng et al., 2007
Tiao Wei Cheng Qi Decoction Protects against gastrointestinal disorders, and liver diseases Tseng et al., 2007
Fenofibrate Inhibits TNF-α and up-regulates PPAR-α and protects against NAFLD Hong et al., 2007
Xuezhikang Inhibits TNF-α and protects against NAFLD Hong et al., 2007
Breviscapine extracted herb Erigeron breviscapus Attenuating liver lipid accumulation and oxidative stress Wu et al., 2007a,b
Inchinkoto Increased hepatic levels of heme oxygenase-1 and GSH by a nuclear
factor-E2-related factor (Nrf2)-dependent mechanism
Okada et al., 2007
Tanshinones Decreases ALT and MDA levels, and increases ORAC, vitamin C and GSH levels in
liver tissues
Xu et al., 2006
Root of Bupleurus spp. Inhibitory capacity on superoxide anion formation and superoxide anion scavenging
activity
Liu et al., 2006
BJ-JN (a traditional Chinese formulation) ALT levels, hepatic NO and MDA content, and restores hepatic SOD activity and
alleviates diminished (by toxin treatment) splenocyte proliferation
Zou et al., 2006
Piper betel leave It has the biological capabilities of detoxication, anti-oxidation, and antimutation Young et al., 2007
Cordyceps sinensis Possesses the antitumor activity, antioxidant activity, and the capability of modulating
the immune system
Chen et al., 2006
Baicalin Decreases the leakages of LDH and ALT, and the formation of MDA; attenuates GSH
depletion and oxidative stress. Histopathological evaluation of the rat livers revealed
that baicalin reduced the incidence of liver lesions including hepatocyte swelling,
leukocyte infiltration, and necrosis induced by toxin
Hwang et al., 2005
Crocetin Protective action of crocetin operated via quenching of the superoxide anion and/or
free radical
Tseng et al., 1995
Bidens bipinnata L. Suppresses nitric oxide production and NF-κB activation, and possesses antioxidant
property
Zhong et al., 2007
Mung bean, adzuki bean, black bean, and rice bean Possess antioxidant property and suppresses LPO Wu et al., 2001
laureola), Pennyroyal (Mentha pulegium), Greater celandine
(Chelidonium majus), Kava (Piper methysticum), Black cohosh
(Cimifuga racemosa), Noni juice (Morinda citrifolia), Gotu Kola
(Centella asiatica), etc. are reported to have liver damaging
effects (Stickel and Shouval, 2015). These products when
consumed may cause symptoms ranging from acute, chronic,
cholestatic, fulminant, and acute autoimmune-like hepatitis
to acute liver failure, and liver cirrhosis. The mechanism of
their toxicities are largely unknown; however, involvement
of oxidative stress and apoptosis is also reported (Stickel and
Shouval, 2015).
CONCLUSION
The nature and dose of a particular drug are not the only
determining factors of cell injury. Other factors such as an
individual’s gene expression profile, antioxidant status and the
capacity for regeneration are also crucial. Several mechanisms
are involved in the initiation of liver cell damage and aggravate
ongoing injury processes. Dysfunction of these vital cell
organelles results in impairment of dynamic equilibrium in
homeostatic condition, thus resulting in intracellular oxidative
stress with excessive formation of reactive oxygen species. Major
causes of the hepatotoxic reactions by drugs are elevated ROS
generation, oxidative stress and suppressed immune responses.
Hepatotoxicity remains a major cause of drug withdrawal from
the market. Recent examples in the USA and Europe are
ximelagatran, nefazodone, nimesulide, ebrotidine, trovafloxacin,
troglitazone, bromfenac, and so forth.
Natural products have shown great promise in combating
against the toxicity of several commonly used drugs, including
acetaminophen and paracetamol. Additionally, some of these
natural products, such as resveratrol and curcumin, are now
widely accepted chemopreventive agents. Due to easy availability
and dietary nature, it is time to promote the natural products as
supplementary medication with drugs that also cause toxicity to
cells. Although amajority of natural products investigated to date
are non-toxic, some studies have shown liver toxicity by certain
natural products. Therefore, the proper selection of the natural
products is also necessary. It is envisioned that natural products
will not only lower the risk of drug-induced liver damage, but
also provide an alternative solution to remedy the drug-induced
hepatotoxicity.
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